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Interaction Between
Use of Beta-Blockers and
Statins on Cardiovascular
Outcomes Among
Patients With or At Risk
for AtherothrombosisFor many years, some have suggested that beta-
blockers modify the metabolic proﬁle of patients
treated for high blood pressure. A pre-speciﬁed anal-
ysis of ASCOTAnglo-SCandinavian Outcomes Trial) (1)
assessing the synergistic effects of lipid-lowering and
blood-pressure-lowering therapies suggested a nega-
tive interaction between beta-blockers and statins, as
compared with calcium-channel blockers (CCBs) and
statins, with an increased rate of ischemic events
among patients receiving both therapies. However,
this observation was not ofﬁcially conﬁrmed (2) and
therefore uncertainty persists. Given that many pa-
tients receive both types of agents, particularly in
secondary prevention after acute coronary syn-
dromes, clarifying whether such an interaction exists
or not is important. A recent analysis of beta-blocker
use in stable atherothrombotic patients failed to show
a beneﬁt of beta-blockers in this population (3).
Whether this lack of beneﬁt is due to a worsened
metabolic proﬁle on beta-blockers remains unknown.
We sought to study whether a negative interaction
exists between beta-blocker use and the beneﬁt of
statins in patients with atherothrombosis treated
in primary or secondary prevention, using the REACH
(Reduction in Atherothrombosis for Continued
Health) registry. The design, methods, and main
results of REACH, an international, prospective,
observational study, have been published (4,5).
Brieﬂy, REACH enrolled consecutive patients, aged
45 years or older, with established coronary artery
disease (CAD), cerebrovascular disease (CVD), or
peripheral arterial disease (PAD), or with at least 3
atherothrombotic risk factors. All patients provided
signed informed consent and the institutional review
board in each country approved the protocol. Thestudy participants enrolled in the REACH registry
were from 7 geographical regions in 44 countries.
Data were collected using standardized case report
forms. Patients were followed up prospectively for 2
years and in selected countries up to 4 years for the
occurrence of cardiovascular outcomes, hospitaliza-
tion, or vascular interventions.
Patients were categorized on the basis of statin
and beta-blocker use at baseline. Interaction between
beta-blocker and statin use was then tested. Analyses
were performed in the entire cohort and in the sub-
sets with established CAD, CVD, or PAD. The primary
endpoint was a composite of cardiovascular death,
nonfatal MI, or nonfatal stroke. Hazard ratios (HRs)
were estimated between groups (no statin versus
statin use).
Because of differences in key baselines character-
istics between comparison groups, we introduced
propensity score adjustment in HRs estimations. Pro-
pensity score was calculated using a multivariable
logistic regressionmodel, with the dependent variable
of “statin use”, and 23 covariates describing baselines
characteristics (sex, age, region, BMI), medical history
(smoking status, history of transient ischemic
stroke, stroke, stable angina, carotid angioplasty or
stenting, carotid surgery, aortic valve stenosis, dia-
betes) and baseline medication (use of aspirin, anti-
coagulant, anti-diabetics agent, lipid-lowering agent
other than statin, CCBs, nitrates, or other anti-anginal
agents, diuretics, angiotensin-converting enzyme in-
hibitors, angiotensin-II receptor antagonists, other
antihypertensive drugs, or peripheral arterial claudi-
cation drug). The same propensity scores were used
for adjustment in global cohort and in subgroups
analyses. Statistical analyses were all performed using
SAS version 9.3 (SAS Institute, Cary, North Carolina).
Based on the REACH registry (n ¼ 65,531), we
assessed statins and beta-blockers at baseline in 65,181
patients (99.5%). Within this cohort, 45,312 patients
(69.5%) were treated by statins and 30,971 patients
(47.5%) by beta-blockers. Regarding the medical his-
tory, 38,758 patients (59.5%) had CAD, 18,102 patients
(27.8%) had CVD, and 7,947 patients (12.2%) had PAD
at baseline. Overall, median follow-up was 37 months
(interquartile range [IQR]: 21 to 45 months).
Statin use was consistently associated with lower
adjusted primary endpoint event rate. This was
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FIGURE 1 Total Death Based on Beta-Blocker and Statin Usage
The image depicts the occurrence of primary or secondary endpoint and of total death according to the beta-blocker and statin use status.
CAD¼ coronary artery disease; CV¼ cardiovascular; CVD¼ cerebrovascular disease; MI¼myocardial infarction; PAD¼ peripheral artery disease.
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846observed among patients treated with beta-blockers
(942 [Kaplan-Meier estimate: 18.0%] vs. 2,346 events
[Kaplan-Meier estimate: 13.6%], HR: 0.79 [95% CI: 0.72
to 0.86]), and also among patients not on beta-blockers
(1,623 [16.9%] vs. 1,877 events [12.5%], HR: 0.73 [95%
CI: 0.68 to 0.79]), for patients receiving statins or not
respectively. There was no interaction between beta-
blocker use and the beneﬁt of statins (p value for
interaction: 0.94). Consistent results were observed
across all patient subsets (Fig. 1), with no evidence of
negative interaction. Furthermore, results were
similar for each of the components of the primary
outcome analyzed separately.
There are some limitations to this analysis. The
type of beta-blocker was not collected, and it has been
suggested that a negative interaction of beta-blockers
may be more marked for nonselective beta-blockers or
for those with sympathomimetic activity. Although
propensity score matching adjusts for baseline dif-
ferences, the possibility of residual confounding
cannot be ruled out. Furthermore, unlike ASCOT, a
randomized trial with comparable groups, our data are
from a registry, probably ruling out a quantitative but
not qualitative interaction.
In this large international contemporary cohort for
those patients at risk for atherothrombosis or not,
there was no evidence of a negative interaction be-
tween beta-blockers and the beneﬁt of statins on
cardiovascular outcomes.Jérémie Abtan, MDy
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Concentrations Improves
Management of the
Effects of DabigatranWith interest we read the report by Reilly et al. (1) in a
recent issue of the Journal regarding the effect of
dabigatran plasma concentrations and patient char-
acteristics on the frequency of ischemic stroke and
major bleeding in patients with atrial ﬁbrillation. We
have the following comments and concerns.
Dabigatran is a substrate of the P-glycoprotein
system (P-gp). Many drugs are known to inhibit or
induce the activity of P-gp (2). Was there any associa-
tion between comedication of drugs affecting P-gp
activity and plasma concentrations of dabigatran? It
is known that P-gp activity is dependent on poly-
morphisms (3). Did the authors investigate the preva-
lence of P-gp polymorphisms and its association with
dabigatran levels?
Because metabolization of a substance also de-
pends on diurnal rhythms, it would be interesting to
know if the samples were all taken at the same time of
the day. Renal function may deteriorate over time,
especially in elderly patients, due to comorbidities.
Did the authors observe an increase of plasma dabi-
gatran levels in patients whose renal function deteri-
orated over time?Were the plasma levels of dabigatran
correlated with renal function? What was the optimalrange of dabigatran to prevent both ischemia and
bleeding?
Table 2 in the report by Reilly et al. (1) shows that
dabigatran plasma concentrations were higher in
patients 75 years of age or older, but no data are given
for patients older than 80 years of age. Because many
patients with atrial ﬁbrillation are older than 80 years
of age, it would be interesting to analyze the results in
this subgroup of patients more precisely.
What was the time interval between measurement
of the dabigatran level and occurrence of the bleeding
or ischemic event? Did patients with higher levels
develop bleeding earlier than patients with lower
levels, and did patients with low levels develop
ischemic events earlier than patients with higher
levels? Were there any patients in whom plasma
dabigatran levels were investigated at the time when
the bleeding or ischemic event occurred? Was the
volume of the bleeding or the size of the ischemic
stroke correlated with the dabigatran levels?
The authors report only the association of plasma
dabigatran levels with major bleeding. It would be of
interest to know if this association was also found in
patients with minor bleeding.
In the discussion, it is mentioned that an assay of
dabigatran concentration is not yet available. When
will this assay be available?
The RE-LY (Randomized Evaluation of Long-Term
Anticoagulation Therapy) study was published in
2009. Since that time, the drug has been used
in thousands of patients, and many bleeding and
ischemic episodes have been reported outside clinical
trials (4). Whywere the results of the present study not
reported sooner than 5 years after publication of the
RE-LY study? Knowledge of the importance of dabi-
gatran levels would have saved some of these patients.
Overall, this study provides evidence that preven-
tion of ischemic stroke by dabigatran is dependent on
the plasma concentration of the drug and cannot be
managed simply by using 2 different types of dosages.
There is a strong need to determine the dose of this
drug according to the plasma concentration and to ﬁnd
the optimal plasma concentration that best prevents
the recurrence of stroke but also the occurrence of a
bleeding event.*Claudia Stöllberger, MD
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